Tag: Luke Gill

Clinical Research: Phase 1 - Phase 4

Boosting Immuno-Oncology’s Effectiveness Against Cancer

Immuno-oncology continues to be an exciting frontier in the fight against cancer. Researchers continue to develop drugs that allow the body to weaponize its own immune system against the growth of new tumors. Most uses of immunotherapies have been limited to cancers, like those in the lungs or pancreas, that produce a strong immune response. In his article...

Consulting

Early-Stage Considerations for Maximizing Success in Initial Oncology Clinical Trials

There’s a lot to consider when investigating a novel and targeted oncology compound, and decisions you make early on can have profound and lasting implications. In this webinar, Premier Research shows how making sound decisions from the outset can improve your odds of long-term success. Oncology experts, Paul Hallenbeck and Luke Gill, Executive Directors for...